Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Long-Term Prediction
Completed
- Conditions
- Infarction, Myocardial
- Registration Number
- NCT00196261
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Brief Summary
The purpose of this study is to investigate the performance of established and new risk preditors in predicting long term-mortality (up to ten years) of post-infarction patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3500
Inclusion Criteria
acute myocardial infarction
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie arrhythmic risk prediction in post-infarction patients as studied in NCT00196261?
How do novel biomarkers in NCT00196261 compare to traditional risk scores like the Framingham or EuroSCORE for long-term mortality prediction in myocardial infarction survivors?
Which specific biomarkers identified in the ISAR-Trial are most predictive of arrhythmic events in post-myocardial infarction patients over a decade?
What adverse events are associated with arrhythmic risk stratification methods evaluated in NCT00196261 and how are they managed clinically?
How does the ISAR-Trial's approach to risk prediction influence current guidelines for post-infarction management compared to other observational studies like the GRACE registry?
Trial Locations
- Locations (2)
Deutsches Herzzentrum Muenchen
🇩🇪Munich, Germany
1. Medizinische Klinik, Klinikum rechts der Isar
🇩🇪Munich, Germany
Deutsches Herzzentrum Muenchen🇩🇪Munich, Germany